CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Morgan Stanley Adjusts Price Target Regeneron Pharmaceuticals to $730 From $788, Maintains Equalweight Rating

Negative
AI Analysis

Summary

Morgan Stanley reduced its price target for Regeneron Pharmaceuticals from $788 to $730 while maintaining an Equalweight rating.

Importance:2/10
Sentiment:
-0.30
price_target_reductionequity_researchvaluation
Related Companies

Read the original article

Published by yahoo_finance on July 8, 2026 9:33 AM

Read Original